Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer	Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder	Active, not recruiting	Phase 2	2026-02-27		NCT04742075

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Arbeitsgemeinschaft Gynaekologische Onkologie Austria	3
Belgian Gynaecological Oncology Group	4
Dutch Gynaecological Oncology Group	2
European Network of Gynaecological Oncological Trial Groups (ENGOT)	34
Hellenic Cooperative Oncology Group	12
Nordic Society of Gynaecological Oncology - Clinical Trials Unit	4
North Eastern German Society of Gynaecological Oncology	8

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Rigshospitalet	København Ø	Denmark	2